Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma.

A DoderoA GuidettiA TucciF BarrettaM NovoL DevizziA ReA PassiA PellegrinelliG PruneriR MiceliA TestiM PennisiM C Di ChioP MatteucciC CarnitiF FacchettiG RossiPaolo Corradini

Published in: Leukemia (2019)

Keyphrases

diffuse large b cell lymphoma
epstein barr virus
end stage renal disease
ejection fraction
prognostic factors
peritoneal dialysis
middle aged
hodgkin lymphoma
patient reported
chronic lymphocytic leukemia